vs
FirstCash Holdings, Inc.（FCFS）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
FirstCash Holdings, Inc.的季度营收约是Bio-Techne的1.6倍（$501.3M vs $311.4M），FirstCash Holdings, Inc.净利率更高（20.8% vs 16.4%，领先4.4%），FirstCash Holdings, Inc.同比增速更快（21.2% vs -1.5%），过去两年FirstCash Holdings, Inc.的营收复合增速更高（16.9% vs 1.3%）
FirstCash Holdings, Inc.是总部位于美国得克萨斯州沃斯堡的典当企业，在美国及拉丁美洲多地运营线下典当零售门店，为纳斯达克证券交易所公开上市企业，在美洲典当服务领域拥有成熟的业务布局与完善的运营网络。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
FCFS vs TECH — 直观对比
营收规模更大
FCFS
是对方的1.6倍
$311.4M
营收增速更快
FCFS
高出22.7%
-1.5%
净利率更高
FCFS
高出4.4%
16.4%
两年增速更快
FCFS
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $501.3M | $311.4M |
| 净利润 | $104.2M | $51.0M |
| 毛利率 | — | 66.9% |
| 营业利润率 | 28.5% | 24.2% |
| 净利率 | 20.8% | 16.4% |
| 营收同比 | 21.2% | -1.5% |
| 净利润同比 | 24.7% | 126.0% |
| 每股收益（稀释后） | $2.35 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCFSTECH
| Q1 26 | — | $311.4M | ||
| Q4 25 | $501.3M | $295.9M | ||
| Q3 25 | $411.0M | — | ||
| Q2 25 | $385.1M | $317.0M | ||
| Q1 25 | $371.1M | $316.2M | ||
| Q4 24 | $413.7M | $297.0M | ||
| Q3 24 | $363.1M | $289.5M | ||
| Q2 24 | $363.5M | $306.1M |
净利润FCFSTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $104.2M | $38.0M | ||
| Q3 25 | $82.8M | — | ||
| Q2 25 | $59.8M | $-17.7M | ||
| Q1 25 | $83.6M | $22.6M | ||
| Q4 24 | $83.5M | $34.9M | ||
| Q3 24 | $64.8M | $33.6M | ||
| Q2 24 | $49.1M | $40.6M |
毛利率FCFSTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
营业利润率FCFSTECH
| Q1 26 | — | 24.2% | ||
| Q4 25 | 28.5% | 18.4% | ||
| Q3 25 | 27.4% | — | ||
| Q2 25 | 21.1% | -7.5% | ||
| Q1 25 | 30.0% | 12.2% | ||
| Q4 24 | 26.5% | 16.0% | ||
| Q3 24 | 23.5% | 13.8% | ||
| Q2 24 | 18.2% | 15.0% |
净利率FCFSTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | 20.8% | 12.8% | ||
| Q3 25 | 20.1% | — | ||
| Q2 25 | 15.5% | -5.6% | ||
| Q1 25 | 22.5% | 7.1% | ||
| Q4 24 | 20.2% | 11.7% | ||
| Q3 24 | 17.9% | 11.6% | ||
| Q2 24 | 13.5% | 13.3% |
每股收益（稀释后）FCFSTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $2.35 | $0.24 | ||
| Q3 25 | $1.86 | — | ||
| Q2 25 | $1.34 | $-0.11 | ||
| Q1 25 | $1.87 | $0.14 | ||
| Q4 24 | $1.86 | $0.22 | ||
| Q3 24 | $1.44 | $0.21 | ||
| Q2 24 | $1.08 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $125.2M | $209.8M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $2.3B | $2.1B |
| 总资产 | $5.3B | $2.6B |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资FCFSTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | $125.2M | $172.9M | ||
| Q3 25 | $130.2M | — | ||
| Q2 25 | $101.5M | $162.2M | ||
| Q1 25 | $146.0M | $140.7M | ||
| Q4 24 | $175.1M | $177.5M | ||
| Q3 24 | $106.3M | $187.5M | ||
| Q2 24 | $113.7M | $152.9M |
总债务FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | $260.0M | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.7B | $346.0M | ||
| Q1 25 | $1.7B | $330.0M | ||
| Q4 24 | $1.7B | $300.0M | ||
| Q3 24 | $1.7B | $300.0M | ||
| Q2 24 | $1.7B | $319.0M |
股东权益FCFSTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.3B | $2.0B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | $1.9B | ||
| Q1 25 | $2.1B | $2.0B | ||
| Q4 24 | $2.1B | $2.1B | ||
| Q3 24 | $2.0B | $2.1B | ||
| Q2 24 | $2.0B | $2.1B |
总资产FCFSTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $5.3B | $2.5B | ||
| Q3 25 | $5.2B | — | ||
| Q2 25 | $4.5B | $2.6B | ||
| Q1 25 | $4.4B | $2.6B | ||
| Q4 24 | $4.5B | $2.7B | ||
| Q3 24 | $4.4B | $2.7B | ||
| Q2 24 | $4.3B | $2.7B |
负债/权益比FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | 0.98× | 0.13× | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | 0.79× | 0.18× | ||
| Q1 25 | 0.83× | 0.16× | ||
| Q4 24 | 0.85× | 0.14× | ||
| Q3 24 | 0.87× | 0.14× | ||
| Q2 24 | 0.85× | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $206.6M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.98× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | $206.6M | — | ||
| Q3 25 | $135.8M | — | ||
| Q2 25 | $116.9M | $98.2M | ||
| Q1 25 | $126.6M | $41.1M | ||
| Q4 24 | $198.1M | $84.3M | ||
| Q3 24 | $113.1M | $63.9M | ||
| Q2 24 | $106.2M | $75.5M |
自由现金流FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M |
自由现金流率FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% |
资本支出强度FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% |
现金转化率FCFSTECH
| Q1 26 | — | — | ||
| Q4 25 | 1.98× | — | ||
| Q3 25 | 1.64× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | 1.51× | 1.82× | ||
| Q4 24 | 2.37× | 2.42× | ||
| Q3 24 | 1.74× | 1.90× | ||
| Q2 24 | 2.16× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
